TherapeuticsMD analyst ratings
TherapeuticsMD analyst ratings
While ratings are subjective and will change, the latest TherapeuticsMD (TXMD) rating was a downgraded with a price target of $0.00 to $10.00. The current price TherapeuticsMD (TXMD) is trading at is $9.97, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 06/07/2022 | 0.3% | HC Wainwright & Co. | → $10 | Downgrades | Buy → Neutral |
| 05/06/2022 | -89.97% | Cantor Fitzgerald | $5 → $1 | Downgrades | Overweight → Neutral |
| 03/11/2022 | -74.92% | HC Wainwright & Co. | $3 → $2.5 | Maintains | Buy |
| 11/12/2021 | -69.91% | HC Wainwright & Co. | $4 → $3 | Maintains | Buy |
| 08/07/2020 | -87.96% | Jefferies | $1.25 → $1.2 | Downgrades | Hold → Underperform |
| 05/19/2020 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 05/07/2020 | -49.85% | HC Wainwright & Co. | $6 → $5 | Reiterates | → Buy |
| 04/16/2020 | 50.45% | Stifel | $14 → $15 | Maintains | Buy |
| 02/21/2020 | -39.82% | HC Wainwright & Co. | $7 → $6 | Maintains | Buy |
| 08/14/2018 | 170.81% | Cantor Fitzgerald | $26 → $27 | Maintains | Overweight |
| 06/15/2018 | 10.33% | JP Morgan | → $11 | Initiates Coverage On | → Overweight |
| 09/08/2017 | -39.82% | Morgan Stanley | → $6 | Initiates Coverage On | → Equal-Weight |
| 07/21/2017 | 0.3% | Deutsche Bank | → $10 | Initiates Coverage On | → Buy |
| 07/11/2017 | — | Oppenheimer | Upgrades | Perform → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 2022 年 7 月 6 日 | 0.3% | HC Wainwright & Co. | → 10 美元 | 降级 | 买入 → 中性 |
| 2022 年 6 月 5 日 | -89.97% | 坎托·菲茨杰拉德 | 5 美元 → 1 美元 | 降级 | 超重 → 中性 |
| 03/11/2022 | -74.92% | HC Wainwright & Co. | $3 → 2.5 美元 | 维护 | 买 |
| 11/12/2021 | -69.91% | HC Wainwright & Co. | 4 美元 → 3 美元 | 维护 | 买 |
| 08/07/2020 | -87.96% | 杰富瑞集团 | 1.25 美元 → 1.2 美元 | 降级 | 持有 → 表现不佳 |
| 2020 年 5 月 19 日 | — | 摩根大通 | 降级 | 超重 → 中性 | |
| 05/07/2020 | -49.85% | HC Wainwright & Co. | 6 美元 → 5 美元 | 重申 | → 购买 |
| 2020 年 4 月 16 日 | 50.45% | Stifel | 14 美元 → 15 美元 | 维护 | 买 |
| 02/21/2020 | -39.82% | HC Wainwright & Co. | 7 美元 → 6 美元 | 维护 | 买 |
| 08/14/2018 | 170.81% | 坎托·菲茨杰拉德 | 26 美元 → 27 美元 | 维护 | 超重 |
| 06/15/2018 | 10.33% | 摩根大通 | → 11 美元 | 启动覆盖范围开启 | → 超重 |
| 09/08/2017 | -39.82% | 摩根士丹利 | → 6 美元 | 启动覆盖范围开启 | → 重量相等 |
| 2017 年 7 月 21 日 | 0.3% | 德意志银行 | → 10 美元 | 启动覆盖范围开启 | → 购买 |
| 07/11/2017 | — | 奥本海默 | 升级 | 表现 → 跑赢大盘 |
TherapeuticsMD Questions & Answers
TherapeuticsMD 问题与解答
The latest price target for TherapeuticsMD (NASDAQ: TXMD) was reported by HC Wainwright & Co. on June 7, 2022. The analyst firm set a price target for $10.00 expecting TXMD to rise to within 12 months (a possible 0.30% upside). 4 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2022年6月7日公布了TherapeuticSMD（纳斯达克股票代码：TXMD）的最新目标股价。该分析公司将目标股价定为10.00美元，预计TXMD将在12个月内升至12个月内（可能上涨0.30％）。去年有4家分析公司公布了评级。
The latest analyst rating for TherapeuticsMD (NASDAQ: TXMD) was provided by HC Wainwright & Co., and TherapeuticsMD downgraded their neutral rating.
HC Wainwright & Co. 对TherapeuticSMD（纳斯达克股票代码：TXMD）的最新分析师评级由HC Wainwright & Co. 提供，TherapeuticSMD 下调了中性评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TherapeuticsMD, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TherapeuticsMD was filed on June 7, 2022 so you should expect the next rating to be made available sometime around June 7, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与TherapeuticSMD的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。TherapeuticSMD的最新评级是在2022年6月7日公布的，因此您应该预计下一个评级将在2023年6月7日左右公布。
While ratings are subjective and will change, the latest TherapeuticsMD (TXMD) rating was a downgraded with a price target of $0.00 to $10.00. The current price TherapeuticsMD (TXMD) is trading at is $9.97, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的TherapeuticSMD（TXMD）评级已下调，目标股价为0.00美元，至10.00美元。TherapeuticSMD（TXMD）目前的交易价格为9.97美元，在分析师的预测区间内。
